Pharmalink reports the approval of key patent for chemotherapy drug Busulipo
16-Apr-2008 -
Pharmalink AB announced that the U.S. Patent and Trademark Office has approved U.S. Patent No. 7,351,427, relating to the pharmaceutical composition, method of preparation and method of treatment by use of busulfan, which is the active agent in Pharmalink's Busulipo(tm). Busulfan is a ...
bone marrow
chemotherapy
clinical trials
+2